Department of Nuclear Medicine, University Hospital Bonn, Germany.
Methods. 2011 Nov;55(3):246-52. doi: 10.1016/j.ymeth.2011.05.003. Epub 2011 Jun 12.
The incidence of hepatocellular carcinoma (HCC) is worldwide sharply on the rise and patients with advanced disease carry a poor prognosis. HCC is the sixth most common cancer and the third leading cause of cancer associated deaths in the world. Intra-arterially administered (131)I-Lipiodol is selectively retained by hepatocellular carcinomas, and has been used as a vehicle for delivery of therapeutic agents to these tumours. In this review we focus on the therapeutic indications, usefulness and methods of treatment with 131-Iodine Lipiodol. The effectiveness of (131)I-Lipiodol treatment is proven both in the treatment of HCC with portal thrombosis and also as an adjuvant to surgery after the resection of HCCs. It is at least as effective as chemoembolization and is tolerated much better. Severe liver dysfunction represents theoretic contraindication for radioembolization as well as for TACE. In such cases (131)I-Lipiodol is an alternative therapy option especially in tumours smaller than 6cm.
原发性肝癌（HCC）的发病率在全球范围内急剧上升，晚期患者预后不良。HCC 是全球第六大常见癌症，也是癌症相关死亡的第三大主要原因。经肝动脉内注入（131）I-碘化油后可被肝癌选择性摄取，并已被用作向这些肿瘤输送治疗剂的载体。在本综述中，我们重点介绍（131）I-碘化油的治疗适应症、用途和治疗方法。（131）I-碘化油治疗在伴有门脉血栓形成的 HCC 治疗以及 HCC 切除术后的辅助治疗中均被证实有效。它至少与化疗栓塞一样有效，且耐受性更好。严重肝功能障碍是放射性栓塞以及 TACE 的理论禁忌症。在这种情况下，（131）I-碘化油是一种替代治疗选择，特别是对于直径小于 6cm 的肿瘤。
